Hints and tips:
Related Special Reports
...Daiichi Sankyo is expected to be the ADC leader in 2028 with nearly $10bn of sales, according to Evaluate....
...Indian telco Bharti Airtel and Japan’s Daiichi Sankyo, Denso, Japan Tobacco, Mitsubishi Electric and Mitsui & Co announce second-quarter earnings....
...The drug has transformed Daiichi Sankyo into an oncology company....
...imports of seafood products from Japan since Tokyo began releasing the water in late August, 12 years after a devastating earthquake and tsunami triggered a meltdown of nuclear reactors at the Fukushima Daiichi...
...Oncologists are hopeful a drug developed by AstraZeneca and Daiichi Sankyo will change how doctors treat the most common type of late-stage breast cancer, after data showed it doubled the progression-free...
...Japanese companies are expected to opt into the new deal, given the fragility of Japan’s energy supply and the mothballing of the majority of its nuclear power stations following meltdowns at the Fukushima Daiichi...
...“This will allow us to significantly increase Daiichi Sankyo’s capability,” Mr Manabe said. “We can allocate the development money that is saved to drugs other than DS-1062.”...
...This is just the latest deal in a post-bubble spree spanning food, pharma and finance: think Daiichi-Sankyo and Ranbaxy, Kirin and Schincariol and Toshiba and Westinghouse....
...Critically, said Blackstone, the sale lays down a price marker as Daiichi Sankyo, Eisai and others also consider sales of their OTC businesses....
...Briefly Pharma groups AstraZeneca and Daiichi Sankyo have signed a deal worth up to $6bn to develop and commercialise one of the Japanese company’s cancer drugs — the second big collaboration between the...
...Indian tycoons Malvinder and Shivinder Singh were found guilty of contempt by the country’s supreme court in a victory for Japan’s Daiichi Sankyo as it works to claim $500m in legal damages from the brothers...
...(FT) News round-up AstraZeneca and Daiichi Sankyo join forces again in $6bn cancer deal (FT) Space entrepreneur Charlie Ergen invests in UK government-backed OneWeb (FT) South Africa’s Steinhoff offers...
...AstraZeneca has struck a deal worth up to $6.9bn with Japan’s Daiichi Sankyo to develop and sell a promising new cancer drug, as the Anglo-Swedish group makes a bolstered oncology push on the back of a recent...
...In its biggest deal for over a decade, it will pay Japan’s Daiichi Sankyo up to $6.9bn for a share in a promising new cancer drug. After the news on Friday, it was investors’ turn to wobble....
...As Japan lifted its state of emergency in late May to reflect falling Covid-19 cases, Daiichi Sankyo launched breast cancer drug Enhertu....
...Prof Leonessa says commercial partnerships are based on co-design and feedback rather than financing. “Industry to us is a partner rather than a funder....
...They came to international prominence in 2008 after agreeing to sell Ranbaxy, their family’s drug company, to Japan’s Daiichi Sankyo for $4.7bn....
...Shivinder and Malvinder Singh came to international attention 10 years ago when they sold their majority stake in Ranbaxy, the pharmaceuticals company founded by their grandfather, to Daiichi Sankyo, the...
...Early this year, it raised $3.5bn via a share placing to help fund the development of a new “blockbuster” cancer drug alongside Japanese pharma group Daiichi Sankyo....
...The Singh brothers were once two of India’s richest billionaires, and came to international prominence in 2008 after agreeing to sell Ranbaxy, their family’s drug company, to Japan’s Daiichi Sankyo for $4.7bn...
...They previously came to international attention with the $4.7bn sale of Ranbaxy, their drugs company, to Daiichi Sankyo of Japan....
...The brothers came to international attention when they sold their majority stake in Ranbaxy, the pharmaceuticals company founded by Bhai Mohan Singh, their grandfather, to Daiichi Sankyo, the Japanese company...
...Sankyo....
...Within five years, however, Mr Jawa had positioned Daikin as the industry leader in India even as two other big Japanese companies — telecoms group NTT DoCoMo and drugmaker Daiichi Sankyo — retreated from...
...The Singh brothers left Fortis earlier this year after being slapped with a Rs35bn ($500m) fine relating to the ill-fated $4.7bn sale of their previous company Ranbaxy to Japan’s Daiichi Sankyo....
International Edition